ImmunoCellular Therapeutics (IMUC)., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers.
IMUC’s lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma
IMUC is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers.
In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer.
The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.
November 17, 2016
RegMed Investors’ (RMi) closing bell analysis, the sector edged UP …
November 16, 2016
RegMed Investors’ (RMi) closing bell analysis, after a sprint…
November 16, 2016
ImmunoCellular Therapeutics (NYSE MKT: IMUC) reverses itself out of a NYSEMKT listing issue
November 15, 2016
RegMed Investors’ (RMi) closing bell analysis, capitulation …
November 14, 2016
RegMed Investors’ (RMi) closing bell analysis, the sector has drifted …
November 11, 2016
RegMed Investors’ (RMi) closing bell analysis, upside lives large yet, the sector still needs to prove itself
November 9, 2016
RegMed Investors’ (RMi) closing bell analysis, beyond the knee jerk reaction of expecting the worse and getting more gains and smaller losses
November 8, 2016
RegMed Investors’ (RMi) closing bell analysis, feel the highs now but, the post-election hangover will be a bummer
November 3, 2016
RegMed Investors’ (RMi) closing bell analysis, pricing is down again as concerns are beyond the sector
November 2, 2016
Regenerative Medicine Earnings Scorecard - Q3/2016 - to date
35 companies, 1 interpreter!
Insight, foresight and recommendation
ImmunoCellular Therapeutics (IMUC) -- Always a disappointment having oipened 1/2 at $0.34, cresting to $0.25 on 2/1 closing 2/16 at $0.24. Just another day traders toy ... it's also still in a research mode - stay away.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.